<span style="line-height: 20.8px;">A Series D funding round has pulled in $22 million for PolyPid, an Israel-based firm developing an antibiotic drug-infused bone substitute for the prevention of postsurgical bacterial infections. The proceeds will be used to support late-stage studies of its lead product, D-Plex.</span>